Flexible perovskite solar cells (f‐PSCs) have attracted great attention because of their unique advantages in lightweight and portable electronics applications. However, their efficiencies are far inferior to those of their rigid counterparts. Herein, a novel histamine diiodate (HADI) is designed based on theoretical study to modify the SnO2/perovskite interface. Systematic experimental results reveal that the HADI serves effectively as a multifunctional agent mainly in three aspects: 1) surface modification to realign the SnO2 conduction band upward to improve interfacial charge extraction; 2) passivating the buried perovskite surface, and 3) bridging between the SnO2 and perovskite layers for effective charge transfer. Consequently, the rigid MA‐free PSCs based on the HADI‐SnO2 electron transport layer (ETL) display not only a high champion power conversion efficiency (PCE) of 24.79% and open‐circuit voltage (VOC) of 1.20 V but also outstanding stability as demonstrated by the PSCs preserving 91% of their initial efficiencies after being exposed to ambient atmosphere for 1200 h without any encapsulation. Furthermore, the solution‐processed HADI‐SnO2 ETL formed at low temperature (100 °C) is utilized in f‐PSCs that achieve a PCE as high as 22.44%, the highest reported PCE for f‐PSCs to date.
A novel-small molecular acceptor with electron-deficient 1,3,5-triazine as the core and perylene diimides as the arms is developed as the acceptor material for efficient bulk heterojunction organic solar cells with an efficiency of 9.15%.
A wide bandgap small molecular acceptor, SFBRCN, containing a 3D spirobifluorene core flaked with a 2,1,3-benzothiadiazole (BT) and end-capped with highly electron-deficient (3-ethylhexyl-4-oxothiazolidine-2-yl)dimalononitrile (RCN) units, has been successfully synthesized as a small molecular acceptor (SMA) for nonfullerene polymer solar cells (PSCs). This SMA exhibits a relatively wide optical bandgap of 2.03 eV, which provides a complementary absorption to commonly used low bandgap donor polymers, such as PTB7-Th. The strong electron-deficient BT and RCN units afford SFBRCN with a low-lying LUMO (lowest unoccupied molecular orbital) level, while the 3D structured spirobifluorene core can effectively suppress the self-aggregation tendency of the SMA, thus yielding a polymer:SMA blend with reasonably small domain size. As the results of such molecular design, SFBRCN enables nonfullerene PSCs with a high efficiency of 10.26%, which is the highest performance reported to date for a large bandgap nonfullerene SMA.
All-inorganic CsPbI 3 perovskite presents preeminent chemical stability and a desirable band gap as the front absorber for perovskite/silicon tandem solar cells. Unfortunately, CsPbI 3 perovskite solar cells (PSCs) still show low efficiency due to high density of defects in solution-prepared CsPbI 3 films. Herein, three kinds of hydrazide derivatives (benzoyl hydrazine (BH), formohydrazide (FH) and benzamide (BA)) are designed to reduce the defect density and stabilize the phase of CsPbI 3 . Calculation and characterization results corroborate that the carboxyl and hydrazine groups in BH form strong chemical bonds with Pb 2 + ions, resulting in synergetic double coordination. In addition, the hydrazine group in the BH also forms a hydrogen bond with iodine to assist the coordination. Consequently, a high efficiency of 20.47 % is achieved, which is the highest PCE among all pure CsPbI 3 -based PSCs reported to date. In addition, an unencapsulated device showed excellent stability in ambient air.Since a cesium lead iodide (CsPbI 3 ) perovskite solar cell (PSC) was first reported in 2015, CsPbI 3 perovskite has attracted great interest due to its excellent chemical stability and appropriate band gap ( � 1.7 eV) as the front sub-cell active layer for tandem solar cells. [1][2][3] Regrettably, the highest power conversion efficiency (PCE) of CsPbI 3 -based
Branched-chain amino acids (BCAA), including leucine (Leu), isoleucine (Ile), and valine (Val), play critical roles in energy homeostasis and lipid metabolism in addition to their other functions, such as in protein metabolism. This study investigated the effects of different dietary BCAA ratios on the intramuscular fat (IMF) content and fatty acid composition in different location of skeletal muscles, including the longissimus dorsi (LD), biceps femoris (BF), and psoas major (PM) muscles of growing pigs, and also examined the mRNA expression levels of genes involved in lipid metabolism in these muscle tissues. The experiment was performed on 40 growing pigs (Large White × Landrace) with a similar initial weight (9.85 ± 0.35 kg). The pigs were randomly assigned to one of five diets: diet A was a positive control and contained 20 % crude protein (CP) with a Leu:Ile:Val ratio of 1:0.51:0.63 according to the recommendation of the National Research Council (NRC); for diets B to E, the CP level was reduced to 17 %, and the Leu:Ile:Val ratios were 1:1:1, 1:0.75:0.75, 1:0.51:0.63, and 1:0.25:0.25, respectively. No significant difference was observed in the average feed intake and feed efficiency of the pigs fed the low protein diet (17 % CP) with BCAA treatments relative to the positive control. However, there was a tendency for increased feed efficiency of the 1:0.75:0.75 group compared with the 1:1:1 group (P = 0.09). The BCAA ratio of 1:0.75:0.75 (17 % CP) increased the IMF content of BF muscle (P < 0.01). Moreover, varied dietary BCAA supplementation with a reduced protein level had different effects on the fatty acid composition of the LD, BF, and PM muscles. The BCAA ratio of 1:0.51:0.63-1:0.75:0.75 (17 % CP) significantly lowered the ratio of n-6 to n-3 polyunsaturated fatty acid in these muscles compared with the positive control group (20 % CP). This effect was associated with an increase in mRNA expression levels of acetyl-CoA carboxylase, lipoprotein lipase, fatty acid transport protein, and fatty acid binding protein 4 in the muscles (P < 0.05). The results indicated that the reduced protein diet (17 % CP) with the BCAA ratio within 1:0.25:0.25-1:0.75:0.75 could increase the IMF content in BF muscle and significantly improve the fatty acid composition in different skeletal muscles accompanied by changes in the expression of genes involved in lipid metabolism, compared with those in the pigs that received adequate dietary protein (20 %), which might result in improved eating quality and nutritional value of the meat.
The morphology plays a key role in determining the charge generation and collection process, thus impacting the performances of organic solar cells (OSCs). The limited selection pool of additives to optimize the morphology of OSCs, especially for the emerging layer‐by‐layer (LbL) OSCs, impeding the improvements of photovoltaic performances. Herein, a new method of using conjugated polymers as the additives to optimize the morphology for improving the photovoltaic performances of LbL‐OSCs is reported. Four polymers of PH, PS, PF, and PCl are developed with different side chains. These polymers exhibit poor performances as donor materials and additives in the BHJ devices, due to the unsuitable energy level alignment and unfavorable molecular interactions. By contrast, they can be served as efficient additives to optimize the PM6 fibril matrix for facilitating the penetration of BTP‐eC9 and forming an intertwined D/A bicontinuous network with a vertical segregation. Such morphology is optimized by side chain engineering, which enables the progressive improvement of the charge separation and collection. As a result, adding a small amount of PCl as the additive, the optimized morphology contributes to a champion PCE of 19.10% with a high FF of 80.5%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.